# A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

> **NCT05610280** · PHASE3 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 1478 (actual)

## Conditions studied

- Hypertriglyceridemia
- Cardiovascular Diseases
- Atherosclerosis

## Interventions

- **DRUG:** Olezarsen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05610280
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-21
- **Primary completion:** 2024-08-08
- **Final completion:** 2025-06-09
- **Target enrollment:** 1478 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05610280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05610280, "A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05610280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*